Loading organizations...

§ Private Profile · Dallas, TX, USA
Biotechnology company developing neuroprotective therapies for neurodegenerative diseases: ALS, Parkinson's, MS, with proprietary antibody technology.
GenrAb has raised $5.6M across 1 funding round.
GenrAb has raised $5.6M in total across 1 funding round.
Based in Dallas, Texas, GenrAb is a biotechnology company that develops neuroprotective therapies by isolating fully-human antibodies from the cerebrospinal fluid of patients with neurological diseases. The enterprise utilizes its proprietary Antibody Gene Signature technology to identify treatments for neurodegenerative conditions such as ALS, Parkinson’s, Alzheimer’s, and Multiple Sclerosis, having discovered over 400 potentially therapeutic monoclonal antibodies to date. In April 2025, the organization raised $5.6 million in seed financing led by investment firm Actium to advance its lead candidate, TGM-010, toward upcoming clinical studies. Operating with technology exclusively licensed from UT Southwestern Medical Center, the firm has received industry recognition including Golden Ticket awards from Boehringer Ingelheim and Otsuka Pharmaceuticals. The spinout company, whose exact founding year remains undisclosed, was co-founded by neurologist Dr. Ben Greenberg and is currently led by chief executive officer Larry Tiffany.
GenrAb has raised $5.6M across 1 funding round. Most recently, it raised $5.6M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 22, 2025 | $5.6M Seed | Actium Group | — | Announced |
GenrAb has raised $5.6M in total across 1 funding round.
GenrAb's investors include Actium Group.